Literature DB >> 18995897

Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.

Takaaki Konuma1, Jun Ooi, Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Seiko Kato, Aki Sato, Fumihiko Monma, Senji Kasahara, Kaoru Uchimaru, Tohru Iseki, Arinobu Tojo, Shigetaka Asano.   

Abstract

There are many reports of second allogeneic stem cell transplantation (allo-SCT) using cord blood (CB) for graft failure after initial allo-SCT. However, the efficacy of second allo-SCT using CB for patients with leukemia relapsed after initial allo-SCT is unknown. We report the results of second allo-SCT using CB in seven adult patients with leukemia relapsed after initial allo-SCT. All patients received a myeloablative conditioning regimen including oral busulfan 16 mg/kg, intravenously fludarabine 100mg/m(2) and cyclophosphamide 120 mg/kg. All but one patient had myeloid reconstitution and four patients remain alive at between 4 and 40 months after second SCT. We conclude that second myeloablative allo-SCT using CB may be feasible in selected patients with the relatively younger age, less organ damage and longer time interval between first and second allo-SCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18995897     DOI: 10.1016/j.leukres.2008.10.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.

Authors:  Takanori Ohta; Yasuhiro Sugio; Hiroshi Imanaga; Seidou Oku; Yuju Ohno
Journal:  Int J Hematol       Date:  2019-06-13       Impact factor: 2.490

2.  Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT.

Authors:  Takaaki Konuma; Seiko Kato; Jun Ooi; Yasuhiro Ebihara; Shinji Mochizuki; Maki Oiwa-Monna; Arinobu Tojo; Satoshi Takahashi
Journal:  Int J Hematol       Date:  2015-02-06       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.